Status
Conditions
Treatments
About
This consumer-use study evaluates the effects of a combined postbiotic and prebiotic supplement regimen on appetite control, cravings, metabolic health, energy, and quality of life in adults aged 18-65 years with a body mass index (BMI) between 25 and 30.
Participants will consume one capsule of resM™ GLP-1 Postbiotic and one scoop of resG prebeet ENERGY Prebiotic daily for 60 days. Data will be collected through daily check-ins, weekly surveys, and quality-of-life questionnaires administered through the Chloe mobile application.
The primary objective is to evaluate changes in appetite control and food cravings over 60 days of supplementation.
Full description
The GLP-1 Optimizer Bundle combines resM™ GLP-1 Postbiotic and resG prebeet ENERGY Prebiotic to support appetite control, cravings, metabolic health, energy, and lifestyle behaviors.
This is a prospective, open-label, single-arm consumer-use study conducted over 60 days in approximately 20 adults aged 18-65 years with BMI between 25 and 30.
Participants will consume:
one capsule of resM™ GLP-1 Postbiotic daily one scoop of resG prebeet ENERGY Prebiotic daily
Assessments will be collected electronically through the Chloe mobile application and include:
appetite and cravings surveys energy and mood assessments quality-of-life questionnaires lifestyle habit surveys consumer satisfaction assessments
The study aims to evaluate consumer-reported changes associated with daily supplementation and lifestyle guidance.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Adults aged 18-65 years BMI between 25 and 30 Generally healthy Willing to comply with study procedures Access to smartphone or internet-enabled device for electronic questionnaires
Exclusion Criteria Pregnant, planning pregnancy, or lactating History of bariatric surgery Prescription weight loss medication use within the past 90 days Current GLP-1 drug use History of substance abuse within the past 6 months Current use of supplements containing overlapping active ingredients Significant medical condition that may interfere with study participation or interpretation of results
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal